The Fevicol Company Just Had a Quietly Excellent Year, Here’s Why

Pidilite’s FY26 was defined by a trend that doesn’t often appear in mature consumer businesses: growth and margin expansion moving in the same direction. Standalone revenue grew close to 12% for the year, and almost all of that came from volumes rather than price increases. That growth held up across both the consumer-facing Consumer & Bazaar business and the more industrial B2B segment, with both posting similar low-double-digit volume gains. None of this came at the cost of profitability either. Margins expanded alongside revenue, and earnings grew faster than sales for the year. For a company whose flagship adhesives and sealants franchise is already the dominant player in a category it effectively created, sustaining double-digit volume growth while becoming more profitable is the kind of combination that’s harder to pull off the bigger a business gets.

That underlying strength matters because it’s the backdrop against which Pidilite’s recent corporate moves start to make sense as a single story rather than three unrelated headlines.

Taking the playbook abroad

The company’s new joint venture in Tanzania is the most straightforward of the three. Pidilite is taking the construction chemicals and waterproofing formula that built its domestic Dr. Fixit franchise and replicating it in East Africa, structured as a majority stake alongside a local partner. It’s a low-risk way to extend something that already works into a market where Pidilite has no presence, rather than betting on anything unproven.

Trading direct ownership for scale

The BuildNext transaction is more layered but follows the same underlying instinct. Pidilite Ventures is swapping its direct stake in BuildNext, a small home-design and project-management startup, for shares in JSW One Platforms, while simultaneously putting in fresh capital to retain a majority economic interest on a fully diluted basis. This isn’t really an exit as it’s been described. It looks more like Pidilite recognising that a small standalone asset couldn’t grow into a large, organised, technology-led home construction business on its own. By moving that stake into a bigger platform with stronger distribution, Pidilite stays exposed to the idea while letting a better-placed partner do the scaling.

A bet maturing into a market price

HomeLane sits a few steps further along that same path. As one of the company’s institutional backers, HomeLane plans to list within the next one to two years, which would mark the point at which an early, illiquid venture bet finally gets a market price. The business isn’t profitable yet, but revenue has been growing at a healthy clip, and losses have been narrowing, suggesting the path toward an IPO is grounded in real progress rather than just market timing.

What it adds up to

Strung together, these three moves describe a company comfortable doing two different things at once. The core chemicals business is being run with enough discipline to grow both volumes and margins, even at scale. The cash generated is being used to place patient bets on adjacent categories in home and construction, without needing to own the entire stack in any of them. The clearest evidence of that capital allocation logic shows up in the dividend numbers: FY26’s payout ratio jumped sharply from under 50% the year before to around 70%. That’s a company signalling that its core business is generating more cash than its adjacency bets currently require, and choosing to return the surplus rather than force it into ventures before they’re ready to absorb it.

_{Disclaimer: Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.}

_{The content in these posts/articles is for informational and educational purposes only and should not be construed as professional financial advice and nor to be construed as an offer to buy /sell or the solicitation of an offer to buy/sell any security or financial products.Users must make their own investment decisions based on their specific investment objective and financial position and using such independent advisors as they believe necessary.}

_{Windmill Capital Team: Windmill Capital Private Limited is a SEBI registered research analyst (Regn. No. INH200007645) based in Bengaluru at No 51 Le Parc Richmonde, Richmond Road, Shanthala Nagar, Bangalore, Karnataka – 560025 creating Thematic & Quantamental curated stock/ETF portfolios. Data analysis is the heart and soul behind our portfolio construction & with 50+ offerings, we have something for everyone. CIN of the company is U74999KA2020PTC132398. For more information and disclosures, visit our disclosures page here.}